Stem cells in sepsis and acute lung injury.

OBJECTIVE Sepsis and acute lung injury continue to be major causes of morbidity and mortality worldwide despite advances in our understanding of pathophysiology and the discovery of new management strategies. Recent investigations show that stem cells may be beneficial as prognostic biomarkers and novel therapeutic strategies in these syndromes. This article reviews the potential use of endogenous adult tissue-derived stem cells in sepsis and acute lung injury as prognostic markers and also as exogenous cell-based therapy. DATA SOURCES A directed systematic search of the medical literature using PubMed and OVID, with particular emphasis on the time period after 2002, was done to evaluate topics related to 1) the epidemiology and pathophysiology of sepsis and acute lung injury; and 2) the definition, characterization, and potential use of stem cells in these diseases. DATA SYNTHESIS AND FINDINGS: When available, preferential consideration was given to prospective nonrandomized clinical and preclinical studies. CONCLUSIONS Stem cells have shown significant promise in the field of critical care both for 1) prognostic value and 2) treatment strategies. Although several recent studies have identified the potential benefit of stem cells in sepsis and acute lung injury, further investigations are needed to more completely understand stem cells and their potential prognostic and therapeutic value.

[1]  A. Zeiher,et al.  Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) , 2002, Clinical research in cardiology : official journal of the German Cardiac Society.

[2]  Arthur S Slutsky,et al.  Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. , 2010, American journal of respiratory and critical care medicine.

[3]  M. Moss,et al.  Acute lung injury but not sepsis is associated with increased colony formation by peripheral blood mononuclear cells. , 2010, American journal of respiratory cell and molecular biology.

[4]  Jian-cheng Xu,et al.  INTRAVENOUS DELIVERY OF BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS IMPROVES SURVIVAL AND ATTENUATES LIPOPOLYSACCHARIDE-INDUCED LUNG INJURY IN RATS , 2010, Shock.

[5]  Choon-Sik Park,et al.  Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis , 2010, Respiratory research.

[6]  C. Delacourt,et al.  Pulmonary effects of keratinocyte growth factor in newborn rats exposed to hyperoxia. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[7]  Jae W. Lee,et al.  Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung , 2009, Proceedings of the National Academy of Sciences.

[8]  D. Büscher,et al.  Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis , 2009, Gut.

[9]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[10]  Y. Zhang,et al.  Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. , 2008, Transplantation proceedings.

[11]  Liwen Chen,et al.  Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound Healing , 2008, PloS one.

[12]  Ming-Wei Lin,et al.  Autologous Transplantation of Endothelial Progenitor Cells Attenuates Acute Lung Injury in Rabbits , 2008, Anesthesiology.

[13]  L. He,et al.  Mesenchymal stem cell‐based angiopoietin‐1 gene therapy for acute lung injury induced by lipopolysaccharide in mice , 2007, The Journal of pathology.

[14]  A. Nauta,et al.  Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.

[15]  G. Pizzolo,et al.  Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. , 2007, Stem cells and development.

[16]  L. Henningsohn,et al.  Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon , 2007, Leukemia.

[17]  V. Levitsky,et al.  Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes , 2007, Journal of leukocyte biology.

[18]  L. Zon,et al.  Teratoma formation assays with human embryonic stem cells: a rationale for one type of human-animal chimera. , 2007, Cell stem cell.

[19]  J. Kastrup,et al.  Bone Marrow–Derived Mesenchymal Cell Mobilization by Granulocyte-Colony Stimulating Factor After Acute Myocardial Infarction: Results From the Stem Cells in Myocardial Infarction (STEMMI) Trial , 2007, Circulation.

[20]  D. Stewart,et al.  Competing Interests: This work was , 2022 .

[21]  Jae W. Lee,et al.  Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1 , 2007, The Journal of Immunology.

[22]  A. Wendel,et al.  Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury , 2007, Respiratory research.

[23]  J. Zijlstra,et al.  Increased circulating endothelial progenitor cells in septic patients: Correlation with survival , 2007, Critical care medicine.

[24]  M. Rojas,et al.  Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[25]  L. Ortiz,et al.  Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.

[26]  M. Yoder,et al.  Working hypothesis to redefine endothelial progenitor cells , 2007, Leukemia.

[27]  E. Seifried,et al.  Transcoronary Transplantation of Functionally Competent BMCs Is Associated With a Decrease in Natriuretic Peptide Serum Levels and Improved Survival of Patients With Chronic Postinfarction Heart Failure: Results of the TOPCARE-CHD Registry , 2007, Circulation research.

[28]  Y. Shang,et al.  Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. , 2007, Journal of the American College of Cardiology.

[29]  J. Prchal,et al.  Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. , 2007, Blood.

[30]  A. Zeiher,et al.  Transcoronary transplantation of progenitor cells after myocardial infarction. , 2006, The New England journal of medicine.

[31]  C. Roussos,et al.  Kinetics of progenitor hemopoetic stem cells in sepsis: Correlation with patients survival? , 2006, BMC infectious diseases.

[32]  David Bryder,et al.  Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. , 2006, The American journal of pathology.

[33]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[34]  H. Leffers,et al.  From embryonic stem cells to testicular germ cell cancer-- should we be concerned? , 2006, International journal of andrology.

[35]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[36]  S. Dimmeler,et al.  Neovascularization and cardiac repair by bone marrow-derived stem cells. , 2006, Handbook of experimental pharmacology.

[37]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[38]  D. Hicklin,et al.  Granulocyte colony‐stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Diane P. Martin,et al.  Incidence and outcomes of acute lung injury. , 2005, The New England journal of medicine.

[40]  J. Till,et al.  Perspectives on the properties of stem cells , 2005, Nature Medicine.

[41]  A. Quyyumi,et al.  Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. , 2005, American journal of respiratory and critical care medicine.

[42]  P. Arner,et al.  Functional studies of mesenchymal stem cells derived from adult human adipose tissue. , 2005, Experimental cell research.

[43]  Oh Young Bang,et al.  Autologous mesenchymal stem cell transplantation in stroke patients , 2005, Annals of neurology.

[44]  M. Rojas,et al.  Bone marrow-derived mesenchymal stem cells in repair of the injured lung. , 2005, American journal of respiratory cell and molecular biology.

[45]  H. Kubo,et al.  Increased circulating endothelial progenitor cells in patients with bacterial pneumonia: evidence that bone marrow derived cells contribute to lung repair , 2005, Thorax.

[46]  D. Stewart,et al.  Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.

[47]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[48]  K. Pollok,et al.  Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. , 2004, Blood.

[49]  R. Bellomo,et al.  Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units , 2004, Intensive Care Medicine.

[50]  M. Fini,et al.  Matrix Metalloproteinase-9 Is Required for Adequate Angiogenic Revascularization of Ischemic Tissues: Potential Role in Capillary Branching , 2004, Circulation research.

[51]  H. Kubo,et al.  Bone Marrow-Derived Progenitor Cells Are Important for Lung Repair after Lipopolysaccharide-Induced Lung Injury 1 , 2004, The Journal of Immunology.

[52]  O. Ringdén,et al.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells , 2003, Transplantation.

[53]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[54]  Duncan Young,et al.  Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland , 2003, Critical care medicine.

[55]  M. Varella‐Garcia,et al.  Human pulmonary chimerism after hematopoietic stem cell transplantation. , 2003, American journal of respiratory and critical care medicine.

[56]  Naftali Kaminski,et al.  Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[58]  Edward Abraham,et al.  Neutrophils and acute lung injury , 2003, Critical care medicine.

[59]  Arshed A. Quyyumi,et al.  Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk , 2003 .

[60]  E. Rivers,et al.  Early goal-directed therapy prevents organ failure and mortality in severe sepsis and septic shock , 2003 .

[61]  M. Makuuchi,et al.  G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. , 2002, Biochemical and biophysical research communications.

[62]  C. Verfaillie,et al.  Origin of endothelial progenitors in human postnatal bone marrow. , 2002, The Journal of clinical investigation.

[63]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[64]  Neil D. Theise,et al.  Multi-Organ, Multi-Lineage Engraftment by a Single Bone Marrow-Derived Stem Cell , 2001, Cell.

[65]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[66]  Gary Garber,et al.  The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000) , 2001 .

[67]  A. Gascoigne,et al.  Circulating endothelial cells in patients with septic shock. , 2001, American journal of respiratory and critical care medicine.

[68]  A. Zeiher,et al.  Apoptosis and Heart Failure: A Critical Review of the Literature Vascular Cell Apoptosis in Remodeling, Restenosis, and Plaque Rupture , 2022 .

[69]  J. Isner,et al.  Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. , 2000, Circulation research.

[70]  T. Murohara,et al.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. , 2000, The Journal of clinical investigation.

[71]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[72]  S. Opal,et al.  Anti-inflammatory cytokines. , 2000, Chest.

[73]  J. Isner,et al.  Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[75]  M. Matthay,et al.  The acute respiratory distress syndrome. , 1996, The New England journal of medicine.

[76]  J. Dhainaut,et al.  Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. , 1999, JAMA.

[77]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[78]  Darwin J. Prockop,et al.  Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta , 1999, Nature Medicine.

[79]  A. Lentsch,et al.  Essential Role of Alveolar Macrophages in Intrapulmonary Activation of NF- κ B , 1999 .

[80]  R. Bucala,et al.  Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 1997, Nature Medicine.

[81]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[82]  R. Deterding,et al.  Keratinocyte growth factor reduces lung damage due to acid instillation in rats. , 1996, American journal of respiratory cell and molecular biology.

[83]  François Gouin,et al.  Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults: A Multicenter Prospective Study in Intensive Care Units , 1995 .

[84]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[85]  G. Koch,et al.  Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .

[86]  S. Nasraway,et al.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.

[87]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[88]  G. B. Pierce,et al.  Teratocarcinogenic and tissue-forming potentials of the cell types comprising neoplastic embryoid bodies. , 1960, Laboratory investigation; a journal of technical methods and pathology.